Made in China: Boehringer-Ingelheim to make first mAb from new Shanghai plant
BeiGene’s tislelizumab will be the first commercial product to be made from Boehringer-Ingelheim’s site in Shanghai, and the first to be made by a foreign CMO in China.
Archives for January 10, 2018
Infliximab monograph adopted by European Pharmacopoeia Commission
European Pharmacopoeia Commission has adopted the first monograph for a monoclonal antibody and is poised to add it to the European Pharmacopoeia.
Microbial CMO Wacker sets up Chiesi for heart attack drug return in US
Wacker Biotech will make the drug substance for Retavase (reteplase) at its German facility after completing a tech transfer from the recombinant enzyme’s original manufacturer Roche.